Loading stock…

BioLife Solutions, Inc. (BLFS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

BioLife Solutions, Inc.

BLFSMarket cap $1.89BPrice $38.6

Country🇺🇸United States

SectorHealthcare

IndustryLife Sciences

Makes bioproduction tools and biopreservation media that keep cells and tissues alive during storage and shipping. Nearly every cell and gene therapy in clinical trials relies on its products to survive the journey from lab to patient.

In Bastion Portfolios?

52W Return+41%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+8%6

Revenue Forecast

Rev CAGR (1y)+19%8

Rev CAGR (3y)+20%9

Rev CAGR (5y)+21%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+53%9

EPS Growth Y+3+171%10

Quality

Margins

EBIT Margin2%2

Net Income Margin54%10

Free Cash Flow Margin7%5

Debt

Net Debt/EBITDA-9.210

Efficiency

ROE13%6

ROA14%9

Earnings Stability22

GEAR+AVERAGE54

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)1241

P/E Ratio (Forward 3y)381

P/BV4.54

EV Multiples

EV/EBITDA Fwd591

EV/EBIT Fwd3191

Yield

Free Cash Flow Yield0.4%3

Dividend Yieldna–

Momentum

Short term

1 month return+9%10

3 month return+42%10

YTD return+60%10

Mid term

Price vs 52wHigh97%10

1 year return+41%9

Long term

3 year return+185%9

5 year return+1%4

Risk Shield

Price Risk

Beta1.42

Volatility44%4

Free Cash Flow

Free Cash Flow Margin7%5

Free Cash Flow Yield0.4%3

Quality

ROCE0%2

Earnings Stability22

Net Debt/EBITDA-9.210

02Growth

Is it actually growing, and how fast?

BLFSBioLife Solutions

Revenue FY25$96M

GROWTH RATING↗

VERY STRONG86 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+21%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+53%9

EPS growth, FY28E+171%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 86% of companies worldwide.

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 8%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 21%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 53%/yr vs revenue 20%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+42%10

YTD return+60%10

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+41%9

3-year return+185%9

5-year return+1%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +185% over three years and +0.6% over five, ahead of 60% of the market.

It's up 41% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%), over three months (+42%) and so far this year (+60%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on BioLife Solutions, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

BLFSBioLife Solutions

Revenue FY25$96M

GROWTH RATING↗

VERY STRONG86 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+8%6

Revenue, next 1Y+19%8

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+21%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+53%9

EPS growth, FY28E+171%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 86% of companies worldwide.

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

Revenue grew 8%/yr over the last 3 years and is set to grow 20%/yr from here.

The runway holds up: revenue is set to grow 21%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 53%/yr vs revenue 20%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG95 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+9%10

3-month return+42%10

YTD return+60%10

MID & LONG-TERM▾SCORE

% of 52-week high97%10

1-year return+41%9

3-year return+185%9

5-year return+1%4

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +185% over three years and +0.6% over five, ahead of 60% of the market.

It's up 41% over the past year, now sitting right at its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+9%), over three months (+42%) and so far this year (+60%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally, and the stock trades near its highs. The market is fully behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on BioLife Solutions, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community